Spots Global Cancer Trial Database for relapsed or refractory
Every month we try and update this database with for relapsed or refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01266811 | Multiple Myelom... | Placebo, Velcad... Siltuximab, Vel... | 18 Years - | Centocor, Inc. | |
| Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma | NCT03458260 | Aggressive Non-... | Pixantrone Ifosfamide Etoposide Rituximab Transplant | 18 Years - | The Lymphoma Academic Research Organisation | |
| BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | NCT04690595 | Relapsed or Ref... | BAFFR-CAR T cel... | 18 Years - | PeproMene Bio, Inc. | |
| Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | NCT05554939 | Non Hodgkin's L... | Allogenic CD19-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma | NCT03742921 | Lymphoma, T-Cel... | Istodax | - | Celgene | |
| AZD1152 in Diffuse Large B-cell Lymphoma | NCT01354392 | Lymphoma | AZD1152 | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | NCT04082936 | Non-Hodgkin Lym... Follicular Lymp... DLBCL Mantle Cell Lym... Marginal Zone L... | imvotamab | 18 Years - | IGM Biosciences, Inc. | |
| Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | NCT01313078 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Pegylated L-Asp... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma | NCT05010005 | T-cell Lymphoma... NK-Cell Lymphom... T-cell Prolymph... T-cell Large Gr... | Ruxolitinib Duvelisib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of TG-1801 in Subjects With B-Cell Lymphoma | NCT03804996 | B-Cell Lymphoma | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | NCT04795713 | Advanced Solid ... Non-small Cell ... Squamous Cell C... | MT-6402 | 18 Years - | Molecular Templates, Inc. | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | NCT01778439 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | NCT03793478 | Acute Myeloid L... | Quizartinib Fludarabine Cytarabine Intrathecal (IT... Etoposide | 1 Month - 21 Years | Daiichi Sankyo | |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02652871 | Leukemia | LY2510924 Idarubicin Cytarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes | NCT01692197 | Leukemia | E7070 Idarubicin Cytarabine Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | NCT04082936 | Non-Hodgkin Lym... Follicular Lymp... DLBCL Mantle Cell Lym... Marginal Zone L... | imvotamab | 18 Years - | IGM Biosciences, Inc. | |
| A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia | NCT02538965 | Leukemia, Myelo... | Lenalidomide | 1 Year - 18 Years | Celgene | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | NCT01778439 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | NCT03236857 | Malignancies Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Neuroblastoma | chemotherapy venetoclax | 0 Years - 25 Years | AbbVie | |
| A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT04860466 | Lymphoma, Non-H... | CC-96673 | 18 Years - | Celgene | |
| CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | NCT05054257 | Relapsed or Ref... Non-Hodgkin's L... Non-Hodgkin's L... | Autologous CAR1... | 18 Years - 80 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04975399 | Multiple Myelom... | CC-92328 | 18 Years - | Celgene | |
| BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | NCT04690595 | Relapsed or Ref... | BAFFR-CAR T cel... | 18 Years - | PeproMene Bio, Inc. | |
| Study of TG-1801 in Subjects With B-Cell Lymphoma | NCT03804996 | B-Cell Lymphoma | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | NCT05253807 | Non-Small Cell ... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | NCT03778073 | B-cell Non Hodg... Richter's Trans... | Cosibelimab Cosibelimab + U... Cosibelimab + U... | 18 Years - | TG Therapeutics, Inc. | |
| Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | NCT04921527 | Ovarian Cancer Relapsed or Ref... Chiauranib Paclitaxel | chiauranib Placebo Paclitaxel | 18 Years - 70 Years | Chipscreen Biosciences, Ltd. | |
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | NCT02961101 | Malignancies Mu... | Anti-PD-1 antib... Decitabine Chemotherapy | 12 Years - 75 Years | Chinese PLA General Hospital | |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01199575 | Chronic Lymphoc... CLL | Revlimid Rituximab | 18 Years - | University of California, San Diego | |
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | NCT02961101 | Malignancies Mu... | Anti-PD-1 antib... Decitabine Chemotherapy | 12 Years - 75 Years | Chinese PLA General Hospital | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | NCT01778439 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) | NCT04245839 | Lymphoma, Non-H... | Fludarabine Cyclophosphamid... JCAR017 | 18 Years - | Celgene | |
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | NCT05370430 | Relapsed or Ref... | BAFFR-CAR T cel... | 18 Years - | PeproMene Bio, Inc. | |
| A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE | NCT00063791 | Multiple Myelom... | Bortezomib | - | Millennium Pharmaceuticals, Inc. | |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01199575 | Chronic Lymphoc... CLL | Revlimid Rituximab | 18 Years - | University of California, San Diego | |
| A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) | NCT04245839 | Lymphoma, Non-H... | Fludarabine Cyclophosphamid... JCAR017 | 18 Years - | Celgene | |
| Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | NCT05554939 | Non Hodgkin's L... | Allogenic CD19-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies | NCT02961101 | Malignancies Mu... | Anti-PD-1 antib... Decitabine Chemotherapy | 12 Years - 75 Years | Chinese PLA General Hospital | |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02652871 | Leukemia | LY2510924 Idarubicin Cytarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| AZD1152 in Diffuse Large B-cell Lymphoma | NCT01354392 | Lymphoma | AZD1152 | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | NCT02081378 | Chronic Myeloge... Philadelphia Ch... | Asciminib (ABL0... Nilotinib Imatinib Dasatinib | 18 Years - | Novartis | |
| Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT00836173 | Diffuse Large B... | RICE GaRD Treatment | 18 Years - | Loyola University | |
| Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | NCT05554939 | Non Hodgkin's L... | Allogenic CD19-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma | NCT02269085 | Lymphoma | Ibrutinib Carfilzomib Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
